Plain-English translation of NCT06869278 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing LCAR-AIO, a new type of treatment made from your own immune cells that have been engineered in a laboratory. The medication is designed to help people with four serious nerve-related autoimmune diseases — multiple sclerosis, neuromyelitis optica spectrum disease, MOG-associated disorders, and myasthenia gravis — when standard treatments haven't worked. The study will examine whether this treatment is safe and how well it works in your body.
Many people with these autoimmune diseases don't improve even after trying standard treatments, and they continue to experience symptoms and disability. This medication represents a new approach that researchers hope could help patients whose conditions have become resistant to conventional therapies.
You likely qualify if…
You likely don't qualify if…
You will have several visits starting with screening tests to make sure you're eligible. Then doctors will collect some of your blood cells through a procedure called apheresis, which takes a few hours. After that, you'll receive mild chemotherapy to prepare your body, followed by an infusion of the engineered cells. You'll then have multiple follow-up visits and tests over time so doctors can carefully monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China